📊 NMTC Key Takeaways
Is NMTC a Good Investment? Thesis Analysis
NeuroOne Medical Technologies demonstrates strong revenue growth (+163.5% YoY) and maintains a healthy balance sheet with minimal debt, but the company is burning cash at an alarming rate (-$3.1M operating cash flow) with negative operating margins (-59%) and persistent unprofitability (-$1.4M net loss). The gross margin of 54.2% suggests product viability, yet operational efficiency deteriorates significantly once operating expenses are considered, indicating the growth is not yet translating to sustainable business operations.
Why Buy NMTC? Key Strengths
- Strong revenue growth of 163.5% YoY demonstrates significant market traction
- Excellent liquidity position with 6.41x current ratio and $3.6M cash reserves
- Minimal debt burden with debt-to-equity of 0.01x and only $55.3K long-term debt
- Healthy gross margin of 54.2% indicates strong product pricing power and manufacturing efficiency
NMTC Investment Risks to Consider
- Severe cash burn of $3.1M in operating activities against only $2.9M revenue indicates unsustainable operations
- Negative operating margin of -59% and net margin of -49.7% show inability to control operating expenses relative to revenue
- Interest coverage ratio of -559.2x reflects lack of profitability to service obligations
- Free cash flow of -$3.2M means the company is consuming cash reserves; at current burn rate, cash runway is approximately 14 months
- Deteriorating profitability despite revenue growth suggests expansion is capital-inefficient
Key Metrics to Watch
- Quarterly operating cash flow trends and path to cash flow breakeven
- Operating margin improvement as the company scales revenue
- Cash burn rate and projected runway of remaining reserves
- Operating expense ratio relative to revenue growth
- Gross margin sustainability as manufacturing scales
- Insider trading activity trends indicating management confidence
NMTC Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 6.41x current ratio provides a solid financial cushion.
NMTC Profitability Ratios
NMTC vs Healthcare Sector
How NEUROONE MEDICAL TECHNOLOGIES Corp compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is NMTC Overvalued or Undervalued?
Based on fundamental analysis, NEUROONE MEDICAL TECHNOLOGIES Corp has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
NMTC Balance Sheet & Liquidity
NMTC 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: NEUROONE MEDICAL TECHNOLOGIES Corp's revenue has grown significantly by 5,007% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.46 indicates the company is currently unprofitable.
NMTC Growth Metrics (YoY)
NMTC Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $2.9M | -$1.4M | $-0.03 |
| Q3 2025 | $825.8K | -$1.5M | $-0.03 |
| Q2 2025 | $1.4M | -$485.3K | $-0.02 |
| Q1 2025 | $977.6K | $1.8M | $0.06 |
| Q3 2024 | $629.9K | -$1.7M | $-0.10 |
| Q2 2024 | $466.2K | -$1.7M | $-0.11 |
| Q1 2024 | $114.6K | -$1.7M | $-0.11 |
| Q3 2023 | $32.0K | -$1.7M | $-0.17 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
NMTC Capital Allocation
NMTC SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for NEUROONE MEDICAL TECHNOLOGIES Corp (CIK: 0001500198)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NMTC
What is the AI rating for NMTC?
NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are NMTC's key strengths?
Claude: Strong revenue growth of 163.5% YoY demonstrates significant market traction. Excellent liquidity position with 6.41x current ratio and $3.6M cash reserves.
What are the risks of investing in NMTC?
Claude: Severe cash burn of $3.1M in operating activities against only $2.9M revenue indicates unsustainable operations. Negative operating margin of -59% and net margin of -49.7% show inability to control operating expenses relative to revenue.
What is NMTC's revenue and growth?
NEUROONE MEDICAL TECHNOLOGIES Corp reported revenue of $2.9M.
Does NMTC pay dividends?
NEUROONE MEDICAL TECHNOLOGIES Corp does not currently pay dividends.
Where can I find NMTC SEC filings?
Official SEC filings for NEUROONE MEDICAL TECHNOLOGIES Corp (CIK: 0001500198) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NMTC's EPS?
NEUROONE MEDICAL TECHNOLOGIES Corp has a diluted EPS of $-0.03.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NMTC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, NEUROONE MEDICAL TECHNOLOGIES Corp has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NMTC stock overvalued or undervalued?
Valuation metrics for NMTC: ROE of -22.5% (sector avg: 15%), net margin of -49.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy NMTC stock in 2026?
Our dual AI analysis gives NEUROONE MEDICAL TECHNOLOGIES Corp a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NMTC's free cash flow?
NEUROONE MEDICAL TECHNOLOGIES Corp's operating cash flow is $-3.1M, with capital expenditures of $40.8K. FCF margin is -109.1%.
How does NMTC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -49.7% (avg: 12%), ROE -22.5% (avg: 15%), current ratio 6.41 (avg: 2).